Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
September 11, 2018
Assignee:
Indiana University Research and Technology Corporation
Abstract: Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including myeloproliferative neoplasms. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.
Type:
Grant
Filed:
February 17, 2012
Date of Patent:
June 12, 2018
Assignees:
NOVARTIS PHARMA AG, INCYTE CORPORATION
Inventors:
Alessandro M. Vannucchi, Costanza Bogani, Paola Guglielmelli
Abstract: Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (?2) adrenoceptor antagonist, and in particular, the specific ?2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.
Type:
Grant
Filed:
May 29, 2014
Date of Patent:
May 22, 2018
Assignee:
Indiana University Research and Technology Corporation
Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.
Type:
Grant
Filed:
September 15, 2015
Date of Patent:
May 1, 2018
Assignee:
VERONA PHARMA PLC
Inventors:
Peter Lionel Spargo, Edward James French, Phillip A. Haywood
Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Type:
Grant
Filed:
November 10, 2013
Date of Patent:
March 27, 2018
Assignees:
CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
Abstract: The invention relates to agents for the control of parasites on animals, comprising an active substance from the group of the phenylpyrazoles and vitamin E or a derivative thereof, such as particularly vitamin E acetate, as well as optionally a further active substance from the group of the pyrethroids and/or optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such agents for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs, cats and ferrets.
Abstract: Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
March 13, 2018
Assignee:
Teikoku Pharma USA, Inc.
Inventors:
Susan Meier-Davis, Jianye Wen, Richard D. Hamlin